Literature DB >> 20531284

Role of allo-SCT for CML in 2010.

N Venepalli1, K Rezvani, S Mielke, B N Savani.   

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. However, for a minority of patients who fail TKI or progress to advanced phase disease, allo-SCT remains the only therapeutic option. This review addresses the current indications for allo-SCT in CML and the role of conditioning (myeloablative vs reduced intensity), donor source (sibling vs volunteer unrelated donor), graft source (BM vs peripheral blood vs cord) and the value of pre-, peri- and post transplant use of TKI in the management of CML.

Entities:  

Mesh：

Year:  2010        PMID： 20531284     DOI： 10.1038/bmt.2010.138

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

Review 2.  Development of an effective therapy for chronic myelogenous leukemia.

Authors:  David W Woessner; Carol S Lim; Michael W Deininger
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

3.  Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.

Authors:  Kazuteru Ohashi; Tokiko Nagamura-Inoue; Fumitaka Nagamura; Arinobu Tojo; Kouichi Miyamura; Takehiko Mori; Mineo Kurokawa; Shuichi Taniguchi; Jun Ishikawa; Yasuo Morishima; Yoshiko Atsuta; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2014-08-02       Impact factor: 2.490

4.  Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.

Authors:  Anne-Louise Latif; Grant McQuaker; Anne Parker; Andrew Clark; Mhairi Copland
Journal:  Leuk Res Rep       Date:  2013-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.